KOD News and Press, Kodiak Sciences Inc From 09/25/20

Graybug Vision (GRAY) has priced its upsized initial public offering of 5.628M (from 4.79M) at $16, at the midpoint of the expected range of $15-$17.Underwriters' over-allotment is an additional 843,750 shares.Trading kicks-off today on the Nasdaq Global Market.Offering is expected ...

Kodiak Sciences (KOD) is based in Palo Alto, California. The company is developing Generation 2.0 therapies against common retinal diseases using its antibody biopolymer conjugates technology. The technology allows increased durability, bioavailability, biocompatibility, and stability of the d...

Graybug Vision (GRAY) has filed a preliminary prospectus for an $86M IPO. More news on: Roche Holding AG, REGENXBIO Inc., Opthea Limited, Healthcare stocks news, IPO News, , Read more ...

Kodiak Sciences (NASDAQ: KOD ) : Q2 GAAP EPS of -$0.58 beats by $0.06 . More news on: Kodiak Sciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights a...

The following slide deck was published by Kodiak Sciences Inc. in conjunction with this Read more ...

PALO ALTO, Calif. , July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors an...

Kodiak Sciences (NASDAQ: KOD ) announces updated data from a Phase 1b clinical trial evaluating lead candidate in KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema...

PALO ALTO, Calif. , July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases today announced promising additional safety, efficacy and durability data ...

PALO ALTO, Calif. , July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301...